French pharmaceutical producer Ipsen plans to start Diferelin drug production at the facilities of Raduga Production, St. Petersburg, this autumn.
French pharmaceutical producer Ipsen has launched contract manufacturing of the Tanakan drug on the core of the St. Petersburg-based Raduga Production plant. Raduga is part of the Rosta pharmaceutical group, one of the largest pharmaceutical distributors in Russia, which also manages the Raduga and Pervaya Pomoshch pharmacy chains.
Planned production is 2 million tablets per year, Ipsen CEO Marc de Garidel said. This is the first instance of localized contract manufacturing in Russia for Ipsen. Ipsen Senior Vice President for Russia and the CIS Marina Veldanova said investment in production is estimated at several hundred thousand euros and that
Ipsen would save up to 15% on logistics from localizing production in Russia. The plant will only handle secondary packaging during the initial stage and then launch a full production cycle, Rosta President David Panikashvili said. Launching the full production cycle requires registration procedures that will take two to three years, he said. Full cycle production is planned at 120 million tablets per year. Tanakan is a neurological drug that is used to reduce memory, vision, hearing and dizziness caused by vascular disorders.
The German company ‘Bayer’ has signed an agreement with the St. Petersburg pharma-producer STPF Polysan for contract production of contract media used in computer and magnetic resonance imaging for diagnostic purposes. According to Bayer General Director Niels Hessmann and Polysan’s main owner Alexander Borisov, the contract is for a ten-year term, but they did not reveal the sum of the contract or the capacity of the production lines.
In 2017, the companies plan to launch industrial production of the medicines Gadovist, Magnevist and Ultravist at the Polisan factory in St. Petersburg. According to the press release, Bayer will provide active pharmaceutical substances, technology, production experience and advice on the project. The German company will also invest in purchasing equipment Polysan requires for production purposes, Borisov says. The production lines already have 50% of the requisite equipment and the rest will be added.
This partnership will meet Russia’s demand for these medicines, substituting for about RUB 2 bn in imports, according to St. Petersburg Governor Georgy Poltavchenko, who was present at the signing of the agreement. RUB 2 bn is the entire Russian market for contrast media, Borisov specified. He went on to say that the medicine produced in Russia would be 15–20% cheaper than when imported. In Russia, in 17% of cases, contrast media from Western Europe are used in X-ray and tomographic studies, this amounting to 60% of the total, Hessmann says. Therefore, the growth potential in this segment is huge.
Polysan manufactures medicines at its own plant in St. Petersburg, the first stage of which has an area of 4900 sq.m. and was started up in 2005, whereas the second came into production in 2012. The enterprise has a capacity of 100 m tablets a year, which will go up to 300 m by 2017, Borisov promises. In April 2016, Polysan will begin construction of the plant’s third stage, which should begin producing in 2017, Borisov said, adding that this third stage would include the company’s scientific and technical centre and capacity for contract production of the Bayer medicines.
The French pharmaceutical manufacturer Ipsen plans to launch contract production of the medicine Tanakan at the Raduga Production factory (part of the Rosta pharma-group) next week, as the companies announced in a joint invitation to the opening ceremony.
Company's website: www.ipsen.com/en/
T: +33 (0)1 58 33 60 09
Contact: Marc de GARIDEL, Chairman of the Board of Directors
Ipsen Pharma is a European pharmaceutical company with about 4 000 employees that produces for the market over 20 medicines and is represented in more than 100 countries.